Back to search results

CT Scans for Pancreatic Cancer Diagnosis and Treatment Response

This study is looking at how well Computed Tomography (CT) scans work in diagnosing people with pancreatic cancer. Researchers want to see if CT scans can help predict how you might respond to chemotherapy, like fluorouracil/irinotecan/leucovorin calcium/oxaliplatin or gemcitabine/nab-paclitaxel. You would receive two CT scans: one before chemotherapy starts and another at your first follow-up visit with your oncologist. You would also complete two short questionnaires about your symptoms. The study aims to see if changes in your CT scans correlate with how well your cancer is controlled. The study is currently recruiting up to 259 participants who have pancreatic cancer that has not spread to distant parts of the body.

Study design
This is an interventional study with a planned enrollment of 259 participants. It is not specified if it is randomized or blinded.
What's involved
You would receive two CT scans and complete two questionnaires. The questionnaires should take about 10 minutes each.
Compensation
Not stated in the trial record.
Follow-up
The primary endpoint is measured at 4 months, looking at the correlation between local control and changes in mass transport by CT.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT02361320

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer

Recruiting
NAAges 18+InterventionalDiagnostic
M.D. Anderson Cancer Center
~259 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:Computed Tomography (CT)Questionnaire

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Correlation Between Local Control and Changes in Mass Transport by Computed Tomography (CT)
Measured over 4 months

Conditions

Pancreatic Cancer

Explore related trials

Hepatocellular CarcinomaIntrahepatic CholangiocarcinomaPancreatic Carcinoma

Where it's being run

1 sites across 1 states
Texas1

Study leadership

  • Eugene Koay · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center

Who to contact

Eugene Koay
[email protected]
713-563-2300
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

PANCREATIC CANCER: Histologically confirmed adenocarcinoma of the pancreas
PANCREATIC CANCER: Non-distant metastatic pancreatic cancer that is either
Unresectable locally advanced disease, defined as primary tumor that involves \> 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that occludes the superior mesenteric vein or portal vein, aorta or inferior vena cava invasion, or superior mesenteric vein invasion below the transverse mesocolon
Borderline resectable disease, defined as primary tumor that involves =\< 180 degrees of the superior mesenteric artery, celiac axis or any of its branches on CT or MRI, primary tumor that involves the superior mesenteric vein causing vein deformity or segmental venous occlusion with a patent vessel above and below suitable for reconstruction, or primary tumor that abuts or encases (\>= 50% of the vessel circumference) a short segment of the common hepatic artery (typically at the gastroduodenal artery origin)
PANCREATIC CANCER: Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
PANCREATIC CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception and to refrain from breast feeding
PANCREATIC CANCER: Patient who has been recommended chemotherapy treatment for pancreatic cancer
PANCREATIC CANCER: Signed study-specific consent form
HEPATOBILIARY CANCER: Diagnosis of
Hepatocellular carcinoma: This may be diagnosed in the following ways:
Pathologically (histologically or cytologically) proven diagnosis of hepatocellular carcinoma (HCC)
At least one solid liver lesion with arterial enhancement and washout on a delayed phase of a multi-phasic CT or MRI in the setting of cirrhosis or chronic hepatitis B or C without cirrhosis
Intrahepatic cholangiocarcinoma: Pathologically (histologically or cytologically) proven diagnosis of intrahepatic cholangiocarcinoma
HEPATOBILIARY CANCER: Patients may have single or multinodular tumors
HEPATOBILIARY CANCER: ECOG PS 0-1
HEPATOBILIARY CANCER: Women of childbearing potential (those who have not undergone a hysterectomy or who have not been postmenopausal for at least 24 consecutive months) must agree to practice adequate contraception
HEPATOBILIARY CANCER: Prior history of surgical resection, chemotherapy, transarterial chemoembolization (TACE), and/or radiofrequency ablation are allowed
HEPATOBILIARY CANCER: Patients may be enrolled if:
The patient is dispositioned to receive definitive radiotherapy
The patient has received definitive radiotherapy within the past two years and has liver protocol CT or MRI scans before radiotherapy and at first restaging after radiotherapy
HEPATOBILIARY CANCER: Signed study-specific consent form

Exclusion

Presence of distant metastasis
Patients whose tumors are defined as resectable
Unstable angina or New York Heart Association grade II or greater congestive heart failure
Evidence of fever or acute infection (chronic infection such as hepatitis virus is acceptable)
Coexisting medical condition that would preclude chemotherapy, radiotherapy, or iodine-based contrast enhanced CT scan
Pregnant women with a positive pregnancy test
Inability to comply with study and/or follow-up procedures
Patients with an active second malignancy with the exception of non-melanoma skin cancer

What this trial measures

  • Correlation Between Local Control and Changes in Mass Transport by Computed Tomography (CT)4 months

    Local tumor progression defined by clinical signs or symptoms of local pancreatic tumor growth (e.g., worsening back/abdominal pain, obstruction, jaundice, etc.) that are documented by the attending clinician and research data coordinator and/or diagnostic imaging evidence of tumor growth. Kaplan-Meier method used to estimate probabilities of LPFS for patients with a normalized AUC ratio \<1 and patients with a normalized AUC ratio \>/=1, respectively. Log rank test applied to compare the LPFS between these two patient groups. Multivariate Cox proportional hazards models fitted to compare the LPFS between the two comparison groups, adjusting for the effects of patients' characteristics and clinical factors.